Making economic evaluations more helpful for treatment choices in haemophilia.

about

Modern Treatments of Haemophilia: Review of Cost-Effectiveness Analyses and Future Directions.Budget impact analysis of the use of extended half-life recombinant factor VIII (efmoroctocog alfa) for the treatment of congenital haemophilia a: the Italian National Health System perspective

P2860

Q45874959-80DEC48D-DCA9-4491-84C0-9F34D38393B4 Q58803191-617CBC41-EC72-42AB-A1E4-6A553718E630

P2860

Making economic evaluations more helpful for treatment choices in haemophilia.

Item

http://www.wikidata.org/entity/Q38767186

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Making economic evaluations more helpful for treatment choices in haemophilia.

@en

type

Item

label

Making economic evaluations more helpful for treatment choices in haemophilia.

@en

prefLabel

Making economic evaluations more helpful for treatment choices in haemophilia.

@en

P1476

Making economic evaluations more helpful for treatment choices in haemophilia.

@en

P2093

M Drummond

http://www.w3.org/2001/XMLSchema#string

N Houwing

http://www.w3.org/2001/XMLSchema#string

P Giangrande

http://www.w3.org/2001/XMLSchema#string

U Slothuus

http://www.w3.org/2001/XMLSchema#string

P2860

Haemophilia A: pharmacoeconomic review of prophylaxis treatment versus on-demand

Guidance for developers of health research reporting guidelines.

A bibliometric review of cost-effectiveness analyses in the economic and medical literature: 1976-2006.

Economic analysis of recombinant activated factor VII versus plasma-derived activated prothrombin complex concentrate in mild to moderate bleeds: haemophilia registry data from the Czech Republic.

Cost-utility analysis of prophylaxis versus treatment on demand in severe hemophilia A

Cost-utility analysis of immune tolerance induction therapy versus on-demand treatment with recombinant factor VII for hemophilia A with high titer inhibitors in Iran

Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party.

Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A.

A systematic review of the cost-effectiveness of rFVIIa and APCC in the treatment of minor/moderate bleeding episodes for haemophilia patients with inhibitors.

Efficacy of recombinant activated factor VII vs. activated prothrombin complex concentrate for patients suffering from haemophilia complicated with inhibitors: a Bayesian meta-regression.

P304

e58-e66

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/HAE.13173

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-01-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28111847

http://www.w3.org/2001/XMLSchema#string

P921

hemophilia

Making economic evaluations more helpful for treatment choices in haemophilia.

about

P2860

P2860

Making economic evaluations more helpful for treatment choices in haemophilia.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921